Gesellschaftsrecht / M&A

Kapitalmarkt

Steuern

Molecular Partners

Homburger News

Homburger and Molecular Partners

On October 25, 2024, Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics announced that it had priced an underwritten offering of 3,642,988 American Depositary Shares (ADSs) representing 3,642,988 new shares at an offering price of USD 5.49 per ADS amounting to gross proceeds of USD 20 m. The offering included participation from a new investor HBM Healthcare Investments Ltd, which is a leading healthcare investor, as well as multiple existing investors.
Molecular Partners currently intends to use the net proceeds from this offering for the development and expansion of its radiopharmaceutical pipeline and platform (Radio-DARPin Therapeutics) and other general corporate purposes.
The Homburger team was led by Dieter Gericke and Karin Mattle (both Corporate / M&amp;A, Capital Markets) and included Stefan Oesterhelt (Tax), Lorenzo Togni, Romain Fakhoury and Hans Glent Abildgaard (all Corporate / M&amp;A, Capital Markets).

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Finanzierungen und Anlageprodukte

Biopas_web_640x140

Homburger and Biopas

On May 22, 2024, Swixx Biopharma, a Swiss-based global commercial platform dedicated to unlocking access to innovative medicines worldwide, announced its strategic expansion into Latin America by acquiring Laboratorios Biopas. Biopas is a leading pharmaceutical company in Latin America, specializing in the in-licensing, marketing, and sale of cutting-edge specialty pharmaceutical products, with annual sales of approx. USD 220 m. The founders of Biopas will become shareholders of Swixx Biopharma. The transaction is expected to close in June or July 2024, subject to regulatory approvals and customary conditions.
The Homburger team advising Biopas and its founders comprises Andreas Müller, Anna Peter, Hans Glent Abildgaard and Harun Cetin (all Corporate / M&amp;A), Stefan Bindschedler (Financing and Investment Products) as well as Reto Heuberger and Philippe Weber (both Tax).

Homburger advises on the sale of Biopas to Swixx Biopharma

Meyer Burger and Homburger

Homburger News 

Share-Image Teamplate Deals-and-Cases

On April 3, 2024, Meyer Burger Technology AG (SIX: MBTN) announced the successful completion of its rights offering, raising gross proceeds of CHF 206.75 m. Shares not subscribed by shareholders were placed with institutional investors at the prevailing market price.
Homburger acted as legal and tax counsel to Meyer Burger in this transaction. The Homburger team was co-led by Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A, Capital Markets) and included Lorenzo Togni (Capital Markets), Jasmin Künzle, Magda Aref, Hans Glent Abildgaard, Thomas Romelli, Cédric Berger, Oliver Dalla Palma, Daniel Wenzinger and Alexander Giger (all Corporate / M&amp;A, Capital Markets), Miguel Sogo and Oliver Mrose (both Corporate / M&amp;A), Eduard De Zordi and Daniel Hulmann (both Financing and Investment Products) as well as Stefan Oesterhelt (Tax).

Hans Glent
Abildgaard

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advises on the sale of Biopas to Swixx Biopharma

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Join the Team

Hans Glent Abildgaard

Karriere

Sprachen

Zulassung

Teams

Hans GlentAbildgaard

Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary Shares

Homburger advises on the sale of Biopas to Swixx Biopharma

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Join the Team

Hans Glent Abildgaard

Karriere

Sprachen

Zulassung

Teams

Hans Glent
Abildgaard